亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會(huì)員登錄|免費(fèi)注冊(cè)|忘記密碼|管理入口 返回主站||保存桌面|手機(jī)瀏覽|聯(lián)系方式|購(gòu)物車
企業(yè)會(huì)員第1年

湖北遠(yuǎn)成藥業(yè)公司  

香精香料,醫(yī)藥原料

搜索
新聞中心
  • 暫無(wú)新聞
產(chǎn)品分類
  • 暫無(wú)分類
聯(lián)系方式
  • 聯(lián)系人:劉俊
  • 電話:86-027-88041009
  • 郵件:gcbb@yccreate.com
  • QQ:2355327095
站內(nèi)搜索
 
榮譽(yù)資質(zhì)
  • 暫未上傳
友情鏈接
  • 暫無(wú)鏈接
吲哚布芬
單價(jià) 面議對(duì)比
詢價(jià) 暫無(wú)
發(fā)貨 湖北武漢市付款后3天內(nèi)
型號(hào) 63610-08-2
過(guò)期 長(zhǎng)期有效
更新 2012-12-20 15:04
 
詳細(xì)信息
吲哚布芬
吲哚布芬
吲哚布芬 英文名 Indobufen
含量:98%以上
別名 易抗凝,Ibustrin,K-3920
化學(xué)名稱:(±)2-(4-(1-氧化-2-異二氫吲哚基)苯基)丁酸
化學(xué)名稱:4-(1,3-二氫-1-氧代-(2H)-異吲哚-2-基)-alpha-乙基
4-(1,3-Dihydro-1-oxo-(2H)-isoindol-2-yl)-alpha-ethylbenzeneacetic acid
分子式 C18H17NO3
分子量 295.34
CAS登錄號(hào) 63610-08-2
用途:是一種抗凝血藥
©2025 湖北遠(yuǎn)成藥業(yè)公司 版權(quán)所有   技術(shù)支持:化工網(wǎng)   訪問(wèn)量:21673  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |